

TANZANIA – PENTAVALENT VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme

1. Country: Tanzania			
2. Grant Number: 1115-TZA-04c-X			
3. Date of Decision Letter: 16 December 2014			
4. Date of the Partnership Framework Agreement: 01 July 2013			
5. Programme Title: New Vaccine Support			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme Duration¹: 2009 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2009-2014	2015	Total ²
Programme Budget (US\$)	US\$75,938,709 ³	US\$5,039,500	US\$80,978,209
10. Vaccine Introduction Grant: n/a			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2009-2014	2015	
Number of Pentavalent vaccines doses		2,480,000	
Number of AD syringes		2,380,200	
Number of safety boxes		26,200	
Annual Amounts (US\$)	US\$875,938,709 ⁵	US\$5,039,500	
12. Procurement agency: UNICEF			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: n/a	
14. Co-financing obligations: Reference code: 1115-TZA-04c-X-C	
According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.	
Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	279,500
Value of vaccine doses (US\$)	US\$533,764
Total Co-Financing Payments (US\$) (including freight)	US\$552,000
15. Operational support for campaigns: n/a	
16. Additional documents to be delivered for future disbursements:	
Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent	15 May 2015
17. Financial Clarifications: n/a	
18. Other conditions: n/a	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014

TANZANIA – PNEUMOCOCCAL VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme

1. Country: Tanzania			
2. Grant Number: 1215-TZA-12c-X			
3. Date of Decision Letter: 16 December 2014			
4. Date of the Partnership Framework Agreement: 01 July 2013			
5. Programme Title: New Vaccine Support			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme Duration¹: 2012 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2012-2014	2015	Total ²
Programme Budget (US\$)	US\$73,680,409 ³	US\$22,808,500	US\$96,488,909
10. Vaccine Introduction Grant: n/a			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2012-2014	2015	
Number of Pneumococcal vaccines doses		5,400,000	
Number of AD syringes		5,989,000	
Number of safety boxes		65,900	
Annual Amounts (US\$)	US\$73,680,409 ⁵	US\$22,808,500	
12. Procurement agency: UNICEF			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: n/a									
<p>14. Co-financing obligations: Reference code: 1215-TZA-12c-X-C According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2015</td> </tr> <tr> <td>Number of vaccine doses</td> <td>320,400</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$1,080,059</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$1,144,500</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	320,400	Value of vaccine doses (US\$)	US\$1,080,059	Total Co-Financing Payments (US\$) (including freight)	US\$1,144,500
Type of supplies to be purchased with Country funds in each year	2015								
Number of vaccine doses	320,400								
Value of vaccine doses (US\$)	US\$1,080,059								
Total Co-Financing Payments (US\$) (including freight)	US\$1,144,500								
15. Operational support for campaigns: n/a									
<p>16. Additional documents to be delivered for future disbursements:</p> <table border="1"> <tr> <td>Reports, documents and other deliverables</td> <td>Due dates</td> </tr> <tr> <td>Annual Progress Report or its equivalent</td> <td>15 May 2015</td> </tr> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or its equivalent	15 May 2015				
Reports, documents and other deliverables	Due dates								
Annual Progress Report or its equivalent	15 May 2015								
17. Financial Clarifications: n/a									
18. Other conditions: n/a									

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014

TANZANIA – ROTAVIRUS VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme

1. Country: Tanzania			
2. Grant Number: 1315-TZA-13b-X			
3. Date of Decision Letter: 16 December 2014			
4. Date of the Partnership Framework Agreement: 01 July 2013			
5. Programme Title: New Vaccine Support			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule			
8. Programme Duration¹: 2013 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2013-2014	2015	Total ²
Programme Budget (US\$)	US\$20,297,340 ³	US\$9,385,500	US\$29,682,840
10. Vaccine Introduction Grant: n/a			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2013-2014	2015	
Number of Rotavirus vaccines doses		3,525,000	
Annual Amounts (US\$)	US\$20,297,340 ⁵	US\$9,385,500	
12. Procurement agency: UNICEF			
13. Self-procurement: n/a			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 1315-TZA-13b-X-C

According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	288,000
Value of vaccine doses (US\$)	US\$733,946
Total Co-Financing Payments (US\$) (including freight)	US\$763,000

15. Operational support for campaigns: n/a

16. Additional documents to be delivered for future disbursements:

Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent	15 May 2015

17. Financial Clarifications: n/a

18. Other conditions: n/a

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014

TANZANIA – MEASLES SECOND DOSE VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme

1. Country: Tanzania																		
2. Grant Number: 1415-TZA-09a-X																		
3. Date of Decision Letter: 15 December 2014																		
4. Date of the Partnership Framework Agreement: 01 July 2013																		
5. Programme Title: New Vaccine Support, Measles second dose, Routine																		
6. Vaccine type: Measles, Measles Rubella The country is approved for measles second dose support; the country started with measles vaccine and the decision letter is revised according to the country's request to switch to measles-rubella vaccine																		
7. Requested product presentation and formulation of vaccine: 10 dose vial, LYOPHILISED																		
8. Programme Duration¹⁶: 2014 - 2015																		
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): <table border="1"> <thead> <tr> <th></th> <th>2014</th> <th>2015</th> <th>Total¹⁷</th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>US\$875,000</td> <td>US\$830,500</td> <td>US\$1,705,500</td> </tr> </tbody> </table>		2014	2015	Total ¹⁷	Programme Budget (US\$)	US\$875,000	US\$830,500	US\$1,705,500										
	2014	2015	Total ¹⁷															
Programme Budget (US\$)	US\$875,000	US\$830,500	US\$1,705,500															
10. Vaccine Introduction Grant: n/a																		
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):¹⁸ <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with GAVI funds in each year</th> <th>2014</th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Number of Measles vaccines doses</td> <td></td> <td>2,125,600</td> </tr> <tr> <td>Number of AD syringes</td> <td></td> <td>1,768,400</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> <td>233,900</td> </tr> <tr> <td>Number of safety boxes</td> <td></td> <td>22,025</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>US\$875,000</td> <td>US\$830,500</td> </tr> </tbody> </table>	Type of supplies to be purchased with GAVI funds in each year	2014	2015	Number of Measles vaccines doses		2,125,600	Number of AD syringes		1,768,400	Number of re-constitution syringes		233,900	Number of safety boxes		22,025	Annual Amounts (US\$)	US\$875,000	US\$830,500
Type of supplies to be purchased with GAVI funds in each year	2014	2015																
Number of Measles vaccines doses		2,125,600																
Number of AD syringes		1,768,400																
Number of re-constitution syringes		233,900																
Number of safety boxes		22,025																
Annual Amounts (US\$)	US\$875,000	US\$830,500																
12. Procurement agency: UNICEF																		

¹⁶ This is the entire duration of the programme.

¹⁷ This is the total amount endorsed by GAVI for the entire duration of the programme.

¹⁸ This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

13. Self-procurement: n/a

14. Co-financing obligations: n/a

15. Operational support for campaigns: n/a

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with GAVI Secretariat

17. Financial Clarifications: The Country shall provide the following clarifications to GAVI*: n/a

**Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements*

18. Other conditions:

Country has presented an official request to GAVI and UNICEF SD to switch from measles vaccine to measles- rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the Rubella component as from September 2014. As such, country will make the required payments to UNICEF SD as indicated in the table below.

	2014	2015
Number of doses of vaccines for Measles Second Dose approved by GAVI.	1,209,400 ¹⁹	2,125,517
Amount for vaccines approved by GAVI in US\$ (excluding freight and insurance).	\$326,538	\$637,655
Number of doses of Measles-Rubella vaccine that can be purchased with GAVI support.	593,705	1,099,405
Number of doses of Measles-Rubella vaccine to be funded by country.	615,695	1,026,112
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	\$338,632	\$595,145

Country understands that vaccines will be purchased only after receipt of full payment of the respective amounts due from Country and GAVI to the procurement agency for the number of doses as indicated in this Decision Letter. In the event that country wishes to revert to measles vaccine, country should inform UNICEF and GAVI immediately in order to agree on an appropriate arrangement.

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014

¹⁹ Out of the total volume approved of 2,419,400 doses for 2014, only the remaining volume not yet shipped of 1,209,400 doses could be replaced by the MR vaccine.